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T20a b s t r a c t
To date, several HIV-1 fusion inhibitors based on the carboxy-terminal leucine/isoleucine heptad repeat
(CHR) region of an HIV-1 envelope protein gp41 have been discovered. We have shown that a synthetic
peptide mimetic of a trimer form of the CHR-derived peptide C34 has potent inhibitory activity against
the HIV-1 fusion mechanism, compared to a monomer C34 peptide. The present study revealed that a
dimeric form of C34 is evidently structurally critical for fusion inhibitors, and that the activity of multi-
merized CHR-derived peptides in fusion inhibition is affected by the properties of the unit peptides C34,
SC34EK, and T20. The ﬂuorescence-based study suggested that the N36-interactive sites of the C34 tri-
mer, including hydrophobic residues, are exposed outside the trimer and that trimerization of C34 caused
a remarkable increase in fusion inhibitory activity. The present results could be useful in the design of
fusion inhibitors against viral infections which proceed via membrane fusion with host cells.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
Newly developed anti-HIV-1 drugs such as protease inhibitors
and integrase inhibitors have contributed to the highly active
anti-retroviral therapy (HAART) for AIDS.1 Entry of human immu-
nodeﬁciency virus type 1 (HIV-1) into target cells is mediated by
its envelope glycoproteins (Env), which are type I transmembrane
proteins consisting of a surface subunit gp120 and a non-covalently
associated transmembrane subunit gp41.2 Sequential binding of
HIV-1 gp120 to its cell receptor CD4 and a co-receptor (CCR5 or
CXCR4) can trigger a series of conformational rearrangements in
gp41 to mediate fusion between viral and cellular membranes.3–5
The protein gp41 is hidden beneath gp120 and its ectodomain con-
tains the helical amino-terminal and carboxy-terminal leucine/iso-
leucine heptad repeat domains NHR and CHR. Regions of NHR and
CHR are involved in membrane fusion, and 36-mer and 34-mer
peptides, derived from NHR and CHR, have been designated as
the N-terminal helix (N36) and C-terminal helix (C34), respectively.
In the membrane fusion of HIV-1, these helices assemble to form a
six-helical bundle (6-HB) consisting of a central parallel trimer of
N36 surrounded by three strands of C34 in an antiparallel hairpinfashion. Synthetic peptides derived from these helices have potent
antiviral activity both against laboratory-adapted strains and
against primary isolates of HIV-1.6–9 They inhibit the membrane fu-
sion stage of HIV-1 infection in a dominant-negative manner by
binding to the counterpart regions of gp41 (NHR or CHR) thereby
blocking formation of the viral gp41 core. Several potent anti-
HIV-1 peptides based on the CHR region have been discovered7,8
and T20 has subsequently been developed by Roche/Trimeris as
the clinical anti-HIV-1 drug, enfuvirtide.8,10–13 T20 is a 36-mer pep-
tide derived from the gp41 CHR sequence and can bind to the NHR
region to inhibit the formation of the 6-HB structure in a dominant-
negative fashion.10 T20 therapy has brought safety, potent
antiretroviral activity, and immunological beneﬁt to patients, but
its clinical application is limited by resistance development. The
C-terminal helix C34 is also a CHR-derived peptide, and contains
the amino acid residues required for the peptide to dock into the
hydrophobic pocket, termed the ‘deep pocket’ of the trimer of the
NHR region. This peptide potently inhibits HIV-1 fusion in vitro.14
To date, several gp41 mimetics, especially for N36 regions, which
assemble these helical peptides with branched peptide-linkers
have been synthesized as antigens.15–19 Our three-helix bundle mi-
metic, which corresponds to the trimeric form of N36, with a novel
template containing C3-symmetric linkers of equal lengths, showed
signiﬁcant potency as a peptide antigen that can produce antibod-
ies with structural-preference.20 In terms of inhibitory activity the
N36 trimer peptide, compared to the N36 monomer, showed only
a stoichiometric increase in inhibition of HIV-1 fusion, a phenome-
non consistent with the results of other studies.21–23 The utilization
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design of the trimermimics of gp41. It is noteworthy that the trimer
form of C34 showed a 100-fold increase in inhibition of fusion com-
pared to the monomer form.24 Multimerization of functional units,
such as synthetic ligands against receptors, generally shows syner-
gistic binding and high binding afﬁnity.25 To explore the mecha-
nism of action of fusion inhibition by the C34 trimer, C34-derived
peptides in the form of monomer, dimer, or trimer were prepared
in this study and as CHR-derived peptides, SC34EK26 and T20 pep-
tides were also studied (Fig. 1). It has been reported that the se-
quence differences of these peptides show different interaction
modes with N36 trimers. Thus, the effects of increased activity in
HIV-1 fusion inhibition were investigated by comparison of the
activities of the multimerized CHR-derived peptides.
2. Results and discussion
2.1. Chemistry
The C-terminal region of gp41 is known to be an assembly site
involving a trimeric coiled-coil conformation. In our synthetic
CHR-derived peptides, CHR-thioester and CHR-REG (Fig. 2A), the
triplet repeat of arginine and glutamic acid (RERERE) was added
to the C-terminal end of the C34 sequence (residues 628–661) to
increase the solubility in buffer solution, and in thioesteriﬁed
CHR-derived peptides, glycine thioester was fused to the C-termi-
nus. The peptides were synthesized by standard Fmoc solid-phase
peptide synthesis. The C3-symmetric template was utilized to form
a triple helix corresponding precisely to the gp41 pre-fusion form.
The template linker has three branches of equal length and pos-
sesses a hydrophilic structure and a ligation site for coupling with
thioesteriﬁed CHR-derived peptides. The template was synthesized
as reported previously24 and for chemoselective coupling between
C34 peptides and the template, native chemical ligation was per-
formed between an unprotected CHR-REG-thioester and a three-
armed cysteine scaffold (Fig. 2B, C).27,28 The trimer forms of other
CHR-derived peptides, SC34EK and T20, were similarly prepared.
For the synthesis of the dimer forms of these peptides, the ratio
of the peptides and the template was controlled in a stoichiometric
manner (Fig. 2B). After the native chemical ligation, the free thiol
groups were blocked by carboxymethylation with iodoacetamide
in the SH-capped peptides. The products were puriﬁed by prepara-
tive HPLC and characterized by ESI-TOF-MS.
2.2. Anti-HIV assays
The fusion inhibitory activity was evaluated. In our previous
study, the C34 trimer, named triC34e, contained free thiol groups
at the ligation sites, and a concern with intermolecular or intramo-
lecular formation of disulﬁde bonds remained. Thus, in this study,
dimer and trimer peptides with and without carboxymethylationFigure 1. Schematic illustration of HIV-1 gp41 and amino acid sequences of C34, SC34
transmembrane domain, respectively. In the sequence of SC34EK, X represents norleuciat the thiol groups, SH-capped and SH-free peptides, respectively,
were prepared. In these dimer and trimer peptides, the inhibitory
activities of the SH-capped peptides were comparable with or
slightly higher than those of the corresponding SH-free peptides.
The presence of the carboxymethyl groups did not affect the fusion
inhibitory activity and consequently, the IC50 values of the SH-
capped peptides are felt to be more reliable. Of the C34 unit pep-
tides, the dimer form peptide, the C34 dimer (SH-capped), showed
a signiﬁcant increase in inhibitory activity compared to the C34
monomer (Table 1). Its IC50 value was nearly equal to that of the
C34 trimer (SH-capped). These results suggest that the C34 units
in the dimer form can bind to the gp41 N36 region in a cooperative
manner. Compared to the C34 unit peptides, SC34EK and T20 units
showed different activity phenomena in multimerized forms. For
SC34EK, the monomer unit showed very high activity in fusion
inhibition. It is known that the SC34EK obtains higher helicity by
the introduction of salt bridges between lysine and glutamic acid
in positions at i and i+4. The positions of substitution of these res-
idues are selected as those having no interaction with N36 trimers.
Thus, SC34EK is suspected to form an amphipathic helix. In the dimer
and trimer forms of SC34EK, the hydrophilic face should be exposed
to buffer solvents and the hydrophobic face, which can interact with
the N36 pocket, might be packed inside. The decrease in inhibitory
activity, especially in the trimer form (5.1-fold, SH-capped), stemmed
from this formation of SC34EK multimers, compared to that of the
SC34EK monomer. For T20 peptides, the C-terminal region has been
shown to have interactions with membranes. The dimer and trimer
of T20 peptides showed 4.3- and 8.6-fold (SH-capped) increases in
fusion inhibitory activity, respectively, compared to the T20 mono-
mer. Although some increase in activity was observed, the effect of
multimerization did not reveal any cooperative interaction. For all
of the peptides, signiﬁcant cytotoxicity was not observed at a concen-
tration below 5 lM.
2.3. Circular dichroism (CD) spectroscopy
To investigate different effects of multimerization of CHR-de-
rived peptides, folded structures of multimerized peptides were
estimated by analysis of CD spectroscopy (Fig. 3). The peptides
were dissolved in 50 mM sodium phosphate buffer, pH 7.2 with
150 mM NaCl. In our previous study, it was observed that C34 pep-
tides tended to form random structures both in the monomer and
in the trimer.24 The spectra of the C34 monomer, dimer, and trimer
(both, SH-capped) displayed minima around 200 nm, indicating
that these peptides form random structures (Fig. 3A). We previ-
ously reported that the N36 monomer N36RE and the N36 trimer
triN36e form a highly structured a-helix and that the helical con-
tent of triN36e was higher than that of N36RE.20,29 In C34 peptides,
multimerization of the peptides did not induce an increase in the
a-helicity of the peptides. On the contrary, SC34EK and T20
peptides showed an increase of minima around 208 and 222, and enfuvirtide (T20). FP and TM represent a hydrophobic fusion peptide and a
ne.
Figure 2. (A) Schematic illustration of CHR-derived peptides. The monomer peptides obtain carboxylate at the C-terminus (R = OH). The monomer units for native chemical
ligation with the templates obtain thioester at the C-terminus (R = SC2H4COOC2H5). (B) Structures of dimers of CHR-derived peptides. The R represent the state of thiol groups,
SH-free or SH-capped by iodoacetamide (R = H or CH2CONH2, respectively). (C) Structures of trimers of CHR-derived peptides. The R represent the state of thiol groups, SH-
free or SH-capped by iodoacetamide (R = H or CH2CONH2, respectively).
Table 1
Fusion inhibitory activity and cytotoxicity of monomer or multimerized CHR-derived
peptides
IC50a (nM) CC50b (lM)
C34 monomer 152 >5
C34 dimer (SH-free) 1.62 >5
C34 dimer (SH-capped) 1.27 >5
C34 trimer (SH-free) 2.25 >5
C34 trimer (SH-capped) 1.28 >5
SC34EK monomer 1.82 >5
SC34EK dimer (SH-capped) 2.14 >5
SC34EK trimer (SH-free) 8.20 >5
SC34EK trimer (SH-capped) 9.34 >5
T20 monomer 465 >5
T20 dimer (SH-capped) 107 >5
T20 trimer (SH-free) 66.8 >5
T20 trimer (SH-capped) 54.1 >5
T20 (NIH)c 45.2 >5
a IC50 values are based on luciferase signals in TZM-bl cells infected with HIV-1
(NL4-3 strain)
b CC50 values are based on the reduction of the viability of TZM-bl cells. All data
are the mean values from at least three experiments.
c The sample was obtained through the NIH AIDS Research and Reference
Reagent Program, which did not contain RERERE or glycine thioester.
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tides increases (Fig. 3B, C). SC34EK is known to form more stableFigure 3. Circular dichroism (CD) spectra of monomer (blue dot), dimer (red dot), and tri
SC34EK (B), and T20 (C). The concentrations of peptides are 6, 3, and 2 (lM) for monoma-helix by the effects of salt bridges26 and the SC34EK monomer
peptide failed to show such effects. The SC34EK monomer has
three repeats of Arg-Glu at the C-terminus and a corresponding in-
crease in solubility. Thus, the hydrophilic residues might inhibit
efﬁcient formation of a-helix in the monomer form or in the
assembled forms. In the dimer and trimer forms of SC34EK, the
peptides showed a signiﬁcant increase of a-helicity (Fig. 3B). These
multimers are assembled by covalent bonds via the template and
the spectra indicated that the peptides could interact with one an-
other to form stable a-helices. The same effect was observed for
multimerization of the T20 peptides (Fig. 3C). Multimerization of
SC34EK and T20 affected fusion inhibitory activity differently (Ta-
ble 1). Thus, this difference might result from a different interac-
tion with N36 peptides. To investigate the difference, the CD
spectra of the complex with N36 peptides were investigated.
When complexed with N36RE which is an N36 derivative with
the triplet repeat of Arg and Glu (RERERE) at the N-terminus,20 all
of the CHR-derived peptides showed similar spectra independent
of the difference of the numbers of unit peptides, that is, monomer,
dimer and trimer. The spectra indicated the complexes of the C34
and N36RE peptides form a stable a-helix (Fig. 4A). The spectrum
of N36RE displayed weak Cotton effects at 208 and 222 (nm). Com-
pared to the previous study, the solvent was changed from 40%
methanol to PBS only with possible weakening of the formation
of a-helices. The spectra of the C34 peptides suggest that the equi-mer (green dot) of CHR-derived peptides. Panels (A–C) depict the spectra for C34 (A),
er, dimer, and trimer (SH-capped), respectively.
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types of peptides. For SC34EK, in comparison between monomer
and dimer, the dimer complex showed higher a-helicity (Fig. 4B).
It is difﬁcult to conclude that the monomer and dimer complexes
form different complex states and the difference in a-helicity
might be caused by the SC34EK peptides that are not included in
the complex with the N36RE peptide. The spectra of the T20 pep-
tides showed that the three types of peptides form similar com-
plexes with the N36RE peptide (Fig. 4C) and individually, the T20
peptides showed a signiﬁcant increase of a-helicity paralleling
the increase of unit numbers (Fig. 3C). In the complexes with the
N36RE peptide, it was suggested that the equilibrium states are
similar in each of the three types of peptides. The a-helicities of
the dimer and the trimer of T20 in the complexes with the
N36RE peptide are lower than those of the corresponding dimer
and trimer of T20 alone, respectively (Figs. 3C and 4C). This indi-
cates that the increased a-helicity of the T20 peptides by multi-
merization was disrupted by the interaction with the N36RE
peptide, and that the T20 peptide shows a interaction mode with
N36RE that is different from the formation of stable a-helical com-
plexes as observed in the C34 peptides.
2.4. Fluorescence-based assays
To explore the reason for the remarkable decrease in fusion
inhibitory activity by trimerization of SC34EK, the interaction
among unit peptide strands was investigated. The SC34EK peptides
are thought to form stable helical bundles through packing of
hydrophobic residues exposing the hydrophilic faces formed by
the introduction of salt bridges between Glu and Lys. The forma-
tion of the stable packing structure of the SC34EK peptides could
weaken interactions with the N36 peptide and to evaluate the
packing effect of the multimerized SC34EK peptides, analysis with
a ﬂuorescent dye, utilized for estimation of the folding stability of
proteins, was applied. In the due course of denaturing by increas-
ing temperatures, hydrophobic residues are exposed.30 A hydro-
phobic dye, SYPRO orange,31 can interact with hydrophobic
residues thereby increasing the ﬂuorescence intensity. By taking
advantage of this phenomena, the states of the multimerized C34
and SC34EK peptides can be estimated. If the hydrophobic residues
are packed in the assembled form of SC34EK, the interaction of the
SC34EK trimer with SYPRO orange could be decreased compared to
that of the C34 timer. As shown in Figure 5A, the monomers of C34
and SC34EK showed similar spectra with low levels of ﬂuorescent
intensity. The trimers of C34 and SC34EK showed spectra with
remarkably higher levels of ﬂuorescent intensity than the corre-
sponding monomers. In addition, the wavelength showing maxi-
mum intensity in the spectra of these trimers was shifted from
625 to 602 nm. These data suggest that the surfaces of these tri-Figure 4. Circular dichroism (CD) spectra of N36RE (black dot) and the complexes of N
derived peptides. Panels (A)-(C) depict the spectra for C34 (A), SC34EK (B), and T20 (C). Th
and trimer (SH-capped), respectively. The concentration of the N36RE peptide is 6 lM.mers have higher hydrophobicity than those of the corresponding
monomers. The C34 trimer showed approximately 1.5-fold stron-
ger ﬂuorescent intensity compared to the SC34EK trimer at the
maxima in the ﬂuorescence spectra (602 nm). High ﬂuorescent
intensity was not observed in an octa-arginine peptide. Thus, this
1.5-fold difference of ﬂuorescent intensity is due to the difference
of hydrophobicity in the surfaces caused by formation of multi-
merization of C34 and SC34EK peptides. In the SC34EK trimer,
since the hydrophobic residues might be efﬁciently packed inside
helical bundles by the trimerization, the increase of hydrophobic-
ity of the peptide surfaces was totally suppressed. Thus, in compar-
ison with the helix sites of the C34 trimer, the N36-interactive sites
of the SC34EK strands tend to be buried inside the trimer, and the
solvent-accessible sites having E-K salt bridges tend to be exposed
outside the trimer. As a result, the SC34EK trimer has more difﬁ-
culty than the SC34EK monomer accessing N36, and thereby the
inhibitory activity of the SC34EK trimer is lower than that of the
SC34EK monomer.
2.5. Biological discussion
Based on our previous study indicating the increased activity in
HIV-1 fusion inhibition by a cooperative action of C34 in the trimer
form, the different sets of CHR-derived peptides in forms of mono-
mer, dimer, and trimer forms were synthesized and evaluated. In
the fusion inhibition assays, the following noteworthy effects were
revealed; (1) dimerization of C34 shows the same cooperative ef-
fect in increases of fusion inhibition as are shown by the C34 tri-
merization, and (2) the activity of multimerized CHR-derived
peptides in fusion inhibition is affected by the properties of unit
peptides C34, SC34EK, and T20.
In the previous study, a dimeric C37 (residues 625–661) variant
did not show any signiﬁcant difference in IC50 values of anti-HIV-1
activity compared to a wild type C37 monomer although the dimer
peptide showed tighter binding than the C37 monomer to the gp41
NHR coiled coil.32 In this study, the C37 dimer was formed via a
disulﬁde bond at the C-terminus after six histidine residues. In
our dimer peptides, the unit peptides are linked by the template
structure and, because of the stretched distance between the unit
peptides in the complex formation with the N36 peptide, the unit
peptides have greater ﬂexibility than the C37 dimeric structure.
Such an effect might lead to activity of the dimeric form of the
C34 peptides that is different from that of C37 peptides. It has been
shown that T-1249, an analogous peptide of enfuvirtide (T20), and
its hydrophobic C-terminal peptide inhibit HIV-1 fusion by inter-
acting with lipid bilayers.33 The tryptophan-rich domain of
T-1249 was shown to play important roles in HIV-1 fusion.34–36
Since enfuvirtide shows a weak interaction with the gp41 core
structure and the C34 sequence lacks the C-terminal lipid binding36RE21 with monomer (blue dot), dimer (red dot), and trimer (green dot) of CHR-
e concentrations of CHR-derived peptides are 6, 3, and 2 (lM) for monomer, dimer,
Figure 5. Fluorescent analysis utilizing SYPRO orange. The spectra are shown as follows; green line, SYPRO orange; blue line, octa-Arg + SYPRO orange; red line, C34
monomer + SYPRO orange; orange line, SC34EK monomer + SYPRO orange; purple line, C34 trimer (SH-capped) + SYPRO orange; pink line, SC34EK trimer (SH-
capped) + SYPRO orange. The peptide concentration is 6 (lM) in all experiments.
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distinct from that of enfuvirtide.37 Our study on the complex struc-
tures of the multimerized CHR-derived peptides and the N36 pep-
tides was performed in aqueous buffer condition. The state of N36
is totally different from the state of gp41 in the membrane fusion
of HIV-1 and host cells. The CHR-derived peptides could access the
N36 peptide more easily than the whole of gp41 because the N36
sequence only contains interactive residues. The complex form of
the CHR-derived peptides could be different from the complex
form in the membrane fusion of HIV-1. If analytical methods are
available with which to observe the state of the complex of the
gp41 trimer and the CHR-derived peptides, more detailed informa-
tion concerning the effects of cooperative interactions in multimer-
ized forms of C34 will be obtained. Fluorescence-based analyses
could be useful to analyze detailed mechanisms of actions for mul-
timerized C34 peptides in fusion inhibition and recently, a ﬂuores-
cence-based study observing the interaction of gp41 in the surface
of cells was reported.38 The present ﬂuorescence-based study sug-
gested that the N36-interactive sites of the C34 trimer including
hydrophobic residues are exposed outside the trimer, and that
the surface state of the C34 trimer is different from that of the
SC34EK trimer. Thus, trimerization of C34 caused a remarkable in-
crease in fusion inhibitory activity whereas trimerization of
SC34EK caused a remarkable decrease in fusion inhibitory activity.
It was shown that C34 and T20 have similar structures in the equi-
librium states of the complexes with N36. For C34, the large in-
creases in fusion inhibition in dimer and trimer forms might be
due to the cooperative binding of monomer units. Since the com-
plex formations with N36 are thought to be similar in the mono-
mer, dimer and trimer forms, the difference of fusion inhibitory
activity might be due to the difference of kinetics of the interaction
with the N36 peptide. In the interaction with gp41 at the fusion
step, it might be difﬁcult for CHR-derived peptides to form the sta-
ble complexes with the trimeric form of gp41 at the NHR region.
The C34 units could interact cooperatively with the trimer form
of gp41 from the speciﬁc side. In the dimer or trimer forms of
C34, this cooperative interaction is plausible, judging by the results
of inhibition assays and CD measurement for the complex with
N36. T20 peptides showed similar structures in the complex with
the N36 peptide. However, the dimer and trimer forms of T20
did not show cooperative effects in inhibitory activity. T20 pep-
tides contains hydrophobic residues at their C-terminus, and it
has been suggested that these residues interact with lipid mem-
branes. It has been indicated that the interaction with lipid bilayersis important as well as the interaction with the N36 region in the
mechanism of action for the T20 monomer peptide in fusion
inhibition.
3. Conclusion
By utilizing the different sets of CHR-derived peptides with
multimerized forms as fusion inhibitors and a new action mecha-
nism, different effects in multimerization which depend on the
properties of unit peptides have been revealed. Our template has
three branched linkers of equal lengths that precisely mimic the
native assembly of C-peptides. The native chemical ligation effec-
tively proceeds by chemoselective coupling in an aqueous medium
of a three-cysteine-armed scaffold with unprotected CHR-derived
peptides containing a C-terminal-thioester. A dimeric form of
C34 is evidently critical as a necessary active structure of fusion
inhibitors. This effect should provide useful information for the
facile design of highly potent fusion inhibitors. As shown in studies
of the soluble C34 derivative, the different form of interaction of
SC34EK peptides could lead to highly inhibitory effects against
enfuvirtide-resistant viruses.26,39 As indicated, the stable helical
form of unit peptides could lead to the decreased effect of multi-
merization of SC34EK units. However, since the activity of multi-
mers is highly dependent on the sequences of unit peptides, the
further optimization of sequences of unit peptides might be possi-
ble. Furthermore, the trimeric C34 was utilized for production of
antibodies against HIV-1 infection although the antisera did not
show distinct neutralizing activity as performed with the N36 tri-
mer.20,40 It would be of interest to utilize those synthetic multi-
mers of C34 derivatives as peptide antigens. In combination with
investigation of the effects against enfuvirtide-resistant strains,
the designs of inhibitors targeting the dynamic supramolecular
mechanism of HIV-1 fusion will be optimized in future studies.
4. Experiments
4.1. Synthesis of trimers of CHR-derived peptides (SH-free
peptides)
TCEPHCl (3.43 mg, 12.0 lmol), 4-mercaptophenylacetic acid
(MPAA) (5.04 mg, 30.0 lmol), 8 M NaOH aq (7 lL) and CH3CN
(68 lL) were dissolved in 0.133 M sodium phosphate buffer
(450 lL, pH 8.9) containing 8 M urea and 2.67 mM EDTA. CHR-de-
rived peptide thioester (C34 thioester: 9.0 mg, 1.48 lmol, SC34EK
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CH3CN (45 lL) and the template (30 lL, 0.450 lmol) dissolved in
50% aqueous CH3CN (0.1% TFA) were then added and the mixture
was stirred for 2 h at 30 C under a nitrogen atmosphere and mon-
itored by HPLC. The obtained ligation products were puriﬁed by re-
verse phase HPLC. The puriﬁed products were lyophilized and
identiﬁed by ESI-TOF-MS; C34 trimer (SH-free): m/z calcd for
C703H1108N205O245S6 [M+H]+ 16533.9, found: 16542.9 (3.0 mg,
0.16 lmol, 35% yield). SC34EK trimer (SH-free): m/z calcd for
C739H1212N208O239S3 [M+H]+ 16921.9, found: 16930.5 (1.9 mg,
0.09 lmol, 20% yield). T20 trimer (SH-free): m/z calcd for
C757H1161N205O245S3 [M+H]+ 17140.4, found: 17148.8 (2.9 mg,
0.15 lmol, 33% yield).
4.2. Synthesis of dimers of CHR-derived peptides (SH-free
peptides)
In the synthesis of C34 dimer (SH-free), TCEPHCl (2.06 mg,
7.2 lmol), 4-mercaptophenylacetic acid (MPAA) (3.03 mg,
18.0 lmol), 8 M NaOH aq (4 lL) and CH3CN (41 lL) were dissolved
in 0.133 M sodium phosphate buffer (270 lL, pH 8.9) containing
8 M urea and 2.67 mM EDTA. The thioesteriﬁed C34 peptide
(2.5 mg, 0.41 lmol), CH3CN (27 lL) and the template (18 lL,
0.27 lmol) dissolved in 50% CH3CN aq (0.1% TFA) were then added
to the mixture. The reaction mixture was stirred for 1.5 h at 30 C
under a nitrogen atmosphere and monitored by HPLC. The ob-
tained product was puriﬁed by reverse phase HPLC. The puriﬁed
product was lyophilized and identiﬁed by ESI-TOF-MS; C34 dimer
(SH-free): m/z calcd for C484H769N139O169S5 [M+H]+ 11392.4, found
11399.1 (0.5 mg, 0.04 lmol, 14% yield).
4.3. Synthesis of dimers and trimers with capped thiol groups at
ligation sites (SH-capped peptides)
TCEPHCl (3.43 mg, 12.0 lmol), MPAA (5.04 mg, 30.0 lmol), 8 M
NaOH aq (7 lL) and CH3CN (68 lL) were dissolved in 0.133 M so-
dium phosphate buffer (450 lL, pH 8.9) containing 8 M urea and
2.67 mM EDTA. CHR-derived peptide thioester (C34 thioester:
4.1 mg, 0.67 lmol, SC34EK thioester: 4.6 mg, 0.67 lmol or T20 thi-
oester: 4.2 mg, 0.67 lmol), CH3CN (45 lL) and the template (30 lL,
0.45 lmol) dissolved in 50% aqueous CH3CN (0.1% TFA) were then
added to the mixture. After stirring for 1 h at 30 C under a nitro-
gen atmosphere, iodoacetamide (12.5 mg, 67.4 lmol) was added
to the mixture, which was stirred for 30 min at 30 C and moni-
tored by HPLC. The obtained products were puriﬁed by reverse
phase HPLC. The puriﬁed products were lyophilized and identiﬁed
by ESI-TOF-MS; C34 dimer (SH-capped): m/z calcd for
C490H778N142O172S5 [M+H]+ 11563.5, found: 11571.5 (1.1 mg,
0.08 lmol, 18% yield). C34 trimer (SH-capped): m/z calcd for
C709H1116N208O248S6 [M+H]+ 16703.9, found: 16715.3 (0.5 mg,
0.03 lmol, 6% yield). SC34EK dimer (SH-capped): m/z calcd for
C478H848N144O168S3 [M+H]+ 11823.2, found: 11829.5 (1.2 mg,
0.08 lmol, 18% yield). SC34EK trimer (SH-capped): m/z calcd for
C691H1221N211O242S3 [M+H]+ 17091.9, found: 17101.4 (0.5 mg,
0.02 lmol, 5% yield). T20 dimer (SH-capped): m/z calcd for
C526H814N142O172S3 [M+H]+ 11967.9, found: 11976.1 (1.0 mg,
0.07 lmol, 16% yield). T20 trimer (SH-capped): m/z calcd for
C763H1170N208O248S3 [M+H]+ 17310.5, found 17321.6 (1.5 mg,
0.08 lmol, 17% yield).
4.4. CD spectra
CD measurements were performed with a J-720 circular dichro-
ism spectropolarimeter equipped with a thermo-regulator (JASCO).
The wavelength dependence of molar ellipticity [h] was monitoredat 25 C from 195 to 250 nm. The peptides were dissolved in PBS
(50 mM sodium phosphate, 150 mM NaCl, pH 7.2).
4.5. Virus preparation
For virus preparation, 293T/17 cells in a T-75 ﬂask were trans-
fected with 10 lg of the pNL4-3 construct by the calcium phos-
phate method. The supernatant was collected 48 h after
transfection, passed through a 0.45 lm ﬁlter, and stored at
80 C as the virus stock.
4.6. Anti-HIV-1 assay
For the viral fusion inhibitory assay, TZM-bl cells (1  104 cells/
100 lL) were cultivated with the NL4-3 virus (10 ng of p24) and
serially diluted peptides. After 48 h cultivation, cells were lysed
and the luciferase activity was determined with the Steady-Glo
luciferase assay system (Promega, WI)41
4.7. Cytotoxicity assay
The cytotoxic effects of peptides were determined by CellTiter
96 Non-Radioactive Cell Proliferation assay system (Promega) un-
der the same conditions as the anti-HIV assay but in the absence
of viral infection.
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